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Factor VII activating protease (FSAP) is associated with cardiovascular diseases and liver ﬁbrosis. To
understand the regulation of its proteolytic activity we have characterized recombinant FSAP-
mutants over-expressed in HEK-293 cells. The secreted FSAP-protein concentration correlated
inversely with the enzymatic activity of the FSAP-mutants. Over-expression of enzymatically active
FSAP decreased cell viability, whereas inactive variants were expressed and secreted in adequate
amounts. The naturally occurring G534E-variant exhibited reduced proteolytic activity. The DEGF-
3 mutant showed diminished binding to and activation by heparin. Hence, regulation of FSAP activ-
ity is dependent on its EGF-3 domain and over-expression of active variants induces cell death.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
The serine protease FVII activating protease (FSAP) consists of
three EGF-domains, a kringle domain and a serine protease domain
and was ﬁrst puriﬁed based on its binding to hyaluronic acid [1,2].
FSAP is predominantly produced in the liver and circulates as an
inactive zymogen in plasma. It is activated by an auto-catalytic
mechanism which is ampliﬁed by polyanions such as heparin or
RNA [3,4]. FSAP can activate FVII and pro-urokinase (uPA) [4] via
cleavage of the respective pro-forms. Its activity can be efﬁciently
inhibited by serine protease inhibitors (SERPINs) such as plasmin-
ogen activator inhibitor (PAI)-1 [5]. Platelet-derived growth factor
(PDGF)-BB, which plays an important role in atherosclerosis and
liver ﬁbrosis [6,7], can be cleaved and inactivated by FSAP.
Two naturally occurring single nucleotide polymorphisms
(SNPs) in FSAP, termed Marburg I (MI) (G534E) and Marburg II
(MII) (E393Q), have been described. MI-FSAP exhibits reduced pro-
teolytic activity [4], is a risk predictor for carotid stenosis [8] and is
associated with the severity of liver ﬁbrosis [7]. MI-FSAP, in con-
trast to wild-type (WT)-FSAP, failed to reduce PDFG-BB-mediated
proliferation of vascular smooth muscle cells (VSMC) [9] as well
as hepatic stellate cells [7]. Hence, in a reciprocal manner FSAP
enzymatic activity correlates with disease status.chemical Societies. Published by E
giessen.de (S.M. Kanse).To date, all the reported studies on FSAP have been performed
with proteins isolated from human plasma. However, for a deﬁni-
tive structure-function analysis it is necessary to produce recombi-
nant FSAP. Through this study we have laid the foundations for the
production of recombinant FSAP and have further characterized
the inﬂuence of different naturally occurring polymorphisms on
FSAP functions. Moreover, we have strengthened the hypothesis
that the EGF-3 domain is important for the activation of FSAP by
polyanions and have found an unexpected function of intracellular
FSAP in regulating cell death.2. Materials and methods
2.1. Materials
FSAP was isolated from human plasma as described before [10].
Unfractionated heparin and heparin–albumin–biotin were from
Sigma (Munich, Germany). PAI-1 was generously provided by Dr.
Paul Declerk (Department of Pharmaceutical Science, Leuven,
Belgium).
2.2. Plasmids and protein expression
Human wild-type FSAP cDNA was derived from human liver
RNA and subsequently cloned into the EcoRI site of pIRESpuro3lsevier B.V. All rights reserved.
Fig. 1. Expression of FSAP-isoforms in HEK-293 cells. (A) After transfection of cells
and transfer into selection medium, the percentage of wells with viable clones was
determined. (B) The amount of FSAP in conditioned medium, was determined by
ELISA (lg/ml, mean ± S.D., n = 3). (C) Supernatants of different FSAP variants,
standardized by ELISA, were analyzed by Western blotting performed with a
mixture of mAb 677 and mAb 1189.
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(E393Q), R313G-cleavage site and H362F-active site mutants were
generated by site-directed mutagenesis. For the DEGF-3 mutant,
the sequence encoding amino acids 150 to 188 was removed.
Expression vectors were transfected into human embryonic kidney
(HEK)-293 cells using Lipofecamine 2000 reagent (Invitrogen, Kar-
lsruhe, Germany). Selection of transformed cells was performed in
96-well plates (5000 cells/well) in the presence of 3 lg/ml puro-
mycin and 10 lg/ml aprotinin (selection medium). FSAP expres-
sion was tested by Western blotting using mAB 677 and mAB
1189 (American Diagnostica, Pfungstadt, Germany). Percentages
of wells with clones (of 96-well plates) were counted to obtain
an index of the efﬁciency of clone generation.
Conditioned medium was produced with 0.2% FCS and an ELISA
was used for the quantiﬁcation of secreted FSAP, as described
before [4].
For inducible FSAP expression, FSAP coding sequence was in-
serted into T-RExTM expression vector pcDNA4/TO (Invitrogen),
transfected into T-RExTM-293 cells (Invitrogen) and cultivated as de-
scribed above. Expression was induced with 0.5 lg/ml tetracycline
(Invitrogen).
2.3. FSAP binding studies
Heparin–albumin–biotin (2 lg/ml), PDGF-BB (1 lg/ml) or poly-
clonal antibody (pAb) against FSAP (2 lg/ml) were immobilized on
microtiter plates in 100 mM sodium carbonate (pH 9.5) over night
at 4 C. Plates were washed with TBS (25 mM Tris–HCl (pH 7.5) and
150 mM NaCl) containing 0.2% (w/v) Tween 20 (TBS-T) and were
blocked with TBS containing 3% (w/v) BSA (Sigma). Conditioned
media of the different FSAP-isoforms were allowed to bind to the
wells. The plates were washed and bound FSAP was detected by
the addition of mAb 677 followed by peroxidase-conjugated sec-
ondary antibody.
2.4. FSAP enzyme activity assay
MAb 677 (2 lg/ml) was immobilized in microtiter plates and
blocked as above. FSAP containing conditioned medium was added
to the wells and pro-uPA activation was measured by adding pro-
uPA (1 lg/ml; Saruplase, Grünenthal, Stohlberg, Germany), and
0.2 mM of the chromogenic substrate S-2444 (L-pyroglutamyl-
glycyl-L-arginine-p-nitroanilinedihydro-chloride) (Haemochrome,
Essen, Germany). Absorbance was followed in a microplate reader
EL 808 (BioTek Instruments, Winooski, OR, USA).
2.5. Western blot analysis
To analyze FSAP protein, a mixture of antibodies directed
against the N-terminal (mAb 1189) and C-terminal end (mAb
677), was used as described before [10].
2.6. Immunocytochemistry
Cells were washed and ﬁxed with 3.7% (w/v) paraformaldehyde,
permeabilized with 0.2% (w/v) Triton-X 100 (Sigma) and blocked
with 3% (w/v) BSA (Sigma). Antibodies against FSAP (mAb 1189
or mAb 677) and cleaved PARP (#9541) (Cell signaling, Danvers,
MA, USA) [11] as well as secondary antibodies labeled with ﬂuo-
roscein isothiocyanate (FITC) or Rhodamine (Dianova, Hamburg,
Germany) were used. Cells were preserved in Vecta-shield (Linaris
Wehrtheim-Bettingen, Germany), containing 40,6-diamidino-2-
phenylindole dehydrate (DAPI) to stain the nuclei and analyzed
using a Leica ﬂuorescence microscope (Wetzlar, Germany). The
percentage of cells positive for FSAP, cleaved PARP and both anti-
gens were quantiﬁed.2.7. Statistical test
The signiﬁcance of the results was determined by using an un-
paired two tailed ‘‘t” test.
3. Results
3.1. Expression of recombinant FSAP-isoforms in HEK-293 cells
The highest number of stably transfected clones were obtained
with empty vector control, R313G-cleavage site mutant, H362F-ac-
tive site mutant and MI SNP, whereas the number of clones ob-
tained with WT, DEGF-3 and MII was very low (Fig. 1A). Amount
of FSAP in the conditioned media was the highest in the case of
R313G, H362F and MI, whereas WT, DEGF-3 and MII contained
very low levels of FSAP protein, and empty vector exhibited no
expression of FSAP (Fig. 1B). To standardize these differences in
FSAP concentration for further experiments, the amounts were cal-
ibrated using ELISA and Western blotting (Fig. 1C). Overall, the
number of stable clones generated as well as the amount of protein
produced increased with decreasing proteolytic activity of the
FSAP variants.
To further understand this phenomenon, we performed FSAP
immunocytochemistry on cells transfected with WT-, MI- and
R313G-FSAP plasmids. WT-FSAP appeared as a dense irregular
structure within the cytoplasm, whereas MI- and R313G-FSAP
(Fig. 2A) exhibited a more granular and dispersed localization. Ini-
tially, the number of cells transfected with WT-FSAP was similar to
those transfected with the other FSAP variants (data not shown).
Hence, we reasoned that cells expressing WT-FSAP had a selective
disadvantage or died, leading to a decrease in viable cells. To test
this issue more systematically an inducible expression system for
Fig. 2. Inﬂuence of FSAP over-expression on cell-phenotype. (A) Confocal microscopy of transiently transfected HEK-293 cells with empty vector, WT-, MI- and R313G-FSAP.
FSAP was stained using mAb 1189 (red) and nuclei with DAPI (blue). White arrows highlight staining for FSAP. (B) Transiently transfected T-RExTM-293 cells with control
vector or vector carrying WT-FSAP, cultivated in growth medium with or without 0.5 lg/ml tetracycline. FSAP is indicated in red, cleaved PARP in green and nuclei in blue.
White arrows highlight staining for cleaved PARP. Calibration bars = 20 lm. (C) The staining for FSAP (red), cleaved PARP (green), and co-localized FSAP and cleaved PARP
(yellow) was quantiﬁed with respect to total cell number in a ﬁeld. (mean ± S.E.M., n = 3).  indicates P < 0.05 and **P < 0.01, using unpaired two tailed ‘‘t” test.
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staining for the apoptosis marker, cleaved PARP [11], was low. In
contrast, when the induction of FSAP expression was switched on
there was a concomitant increase in cleaved PARP staining
(Fig. 2B and C). Over-expression of FSAP led to a 15% decrease in
cell number after 72 h (data not shown). Addition of tetracycline
to cells transfected with the control vector did not show any alter-
ations in FSAP or cleaved PARP staining. As a control, the related
protease uPA was efﬁciently expressed and did not induce apopto-
sis (data not shown). Finally, addition of exogenous plasma-de-
rived FSAP to cells did not induce any apoptosis (data not shown).
3.2. Interaction of FSAP-isoforms with heparin
Previous studies with limited proteolysis of the FSAP protein
have alluded to the role of EGF-3 domain in heparin binding [12].
In accordance, the DEGF-3 variant, lacking the EGF-3 domain,
clearly exhibited diminished heparin binding (Fig. 3A). In contrast,
the recombinant proteins WT-FSAP, MI-FSAP, and R313G-FSAP(Fig. 3A) as well as MII-FSAP and H362F-FSAP (data not shown)
bound to a similar extent to immobilized heparin.
PDGF-BB is one of the targets of FSAP in vascular tissue [9].
Without heparin the binding of WT-FSAP, DEGF-3-FSAP and
R313G-FSAP to PDGF-BB was low, whereas binding to PDGF-BB
was increased by heparin for WT-FSAP and R313G-FSAP, but not
for DEGF-3-FSAP, indicating again the importance of the EGF-3 do-
main of FSAP for proper substrate interaction (Fig. 3B). As a control
the recognition of WT-FSAP, DEGF-3-FSAP, MI-FSAP and R313G-
FSAP by immobilized pAb against FSAP was similar (Fig. 3C). Using
recombinant protein lacking the EGF-3 domain conﬁrmed its
importance for binding to heparin.
3.3. Proteolytic activity of FSAP-isoforms
Heparin binding leads to an auto-activation of latent FSAP,
which subsequently can activate pro-uPA [4]. Under these condi-
tions, WT-FSAP promoted pro-uPA activation more effectively than
DEGF-3-FSAP and MI-FSAP (Fig. 4A, ﬁlled symbols). In the presence
Fig. 3. Binding characteristics of FSAP-isoforms to heparin. (A) WT- (closed circles),
DEGF-3- (open circles), MI- (gray circles) and R313G-FSAP (closed triangles)
(0.003–0.06 lg/ml) were added to immobilized heparin-albumin-biotin. (B) WT-,
DEGF-3- and R313G-FSAP (0.06 lg/ml) were added to immobilized PDGF-BB.
Binding of FSAP-isoforms without (closed columns) or with (open column) heparin
(10 lg/ml) was determined. FSAP binding to PDGF-BB was normalized with respect
to FSAP binding to anti-FSAP pAb. (C) Binding of recombinant FSAP variants to a pAb
against FSAP was tested. Binding was measured with mAb 677 against FSAP,
mean ± S.D. (n = 3).
Fig. 4. Enzymatic activity of different FSAP-isoforms. (A) WT- (circles), DEGF-3-
(squares) and MI-FSAP (triangles) (0.003–0.06 lg/ml) was captured with mAb 677.
Pro-uPA (1 lg/ml) activation without (closed symbols) or with (open symbols)
heparin (1 lg/ml) was measured by the conversion of S-2444, mean ± S.E.M. (n = 4–
6). (B) FSAP inhibition by PAI-1 (0.01 lg/ml), without (closed column) and with
(open column) heparin (1 lg/ml) was measured by the conversion of the direct
chromogenic substrate S-2288, mean ± S.E.M. (n = 3),  indicates P < 0.005, using
unpaired two tailed ‘‘t” test.
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to a 2-fold induction by DEGF-3-FSAP (Fig. 4C, open symbols).
MII-FSAP exhibited a comparable activity to WT-FSAP, whereas
R313G- and H362F-FSAP were inactive towards pro-uPA as would
be predicted (data not shown).WT-FSAP and DEGF-3-FSAP demonstrated a similar amidolytic
activity in contrast to MI-FSAP and R313G-FSAP, both of which
were inactive towards these substrates. In the presence of heparin
the activity of WT-FSAP and MI-FSAP was increased, whereas the
activity of DEGF-3-FSAP remained unchanged (data not shown).
PAI-1 is known to inhibit FSAP efﬁciently in the presence of a poly-
anionic co-factor [5]. PAI-1-dependent inhibition of WT-FSAP, but
not DEGF-3-FSAP, was increased by heparin (Fig. 4B). Hence, the
EGF-3 domain of FSAP is not only important for heparin binding
but contributes largely to the heparin-mediated regulation of FSAP
activity.4. Discussion
Initial attempts to produce FSAP in heterologous expression
systems such as in Escherichia coli and Saccharoymces cerevisiae re-
sulted in none or very low expression rates. In a eukaryotic system
(HEK-293) we were able to produce very low amounts of WT-FSAP.
Expression of WT-FSAP was associated with an irregular cellular
staining pattern for FSAP and concomitant cell death. Indeed FSAP
expressing cells showed signs of apoptosis and the number of via-
ble clones generated was extremely low. This was not a cell spe-
ciﬁc problem, because we observed a similar pattern in CHO
cells. Addition of aprotinin, a serine protease inhibitor that efﬁ-
ciently inhibits FSAP, in the medium, did not alter this pattern,
indicating that FSAP was acting intracellularly. Mutants with re-
duced enzymatic activity exhibited a well dispersed granular pat-
tern within cells, high extracellular protein levels and high
number of viable clones. This pattern was repeated with mouse
WT-FSAP and mouse inactive mutants indicating that there was
no species difference (data not shown). In spite of these difﬁculties,
enough FSAP could be produced to pursue structure function stud-
ies. In all our test systems the recombinant WT-FSAP behaved sim-
ilarly to plasma-derived FSAP. The reason for its intracellular
toxicity may be related to its ability to bind nucleic acids [3]. This
is conﬁrmed by a recent study showing that FSAP can proteolyse
nucleosomes in apoptotic cells [13].
Using recombinant MI-FSAP (G534E) we could conﬁrm our ori-
ginal observations with human plasma-derived material that this
variant has low enzymatic activity [2,9]. In comparison the MII-
FSAP (E393Q), which also exhibits an amino-acid exchange in the
protease domain, showed no difference in activity. As expected,
the cleavage site and active site mutants were completely inactive.
Previous data generated with proteolytic fragments of native
WT enzyme revealed that the EGF-3 domain plays an important
role in the binding of FSAP to negatively charged polyanions such
as heparin or nucleic acids [12]. The EGF-domain, especially in
members of the coagulation system, is important for protein-pro-
tein or protein-cell surface interactions [14]. Here we now demon-
strate that a recombinant variant of FSAP lacking the EGF-3 domain
(DEGF-3) indeed exhibited very low ability to bind to immobilized
heparin, or to undergo a heparin-dependent increase in auto-acti-
vation. This domain is also required for PAI-1-dependent inhibition
of FSAP in the presence of heparin. Hence, we conclude that, sim-
ilar to other members of the coagulation system [14], the EGF-3
domain plays a central role in the regulation of FSAP activity.
Genetic analysis of large populations with respect to FSAP poly-
morphisms and animal model studies indicate that FSAP has a cru-
cial role in atherosclerosis and liver ﬁbrosis [7,9]. We have, for the
ﬁrst time, produced recombinant FSAP and its variants and have
laid the foundation for its more efﬁcient expression through pro-
tein engineering [15]. Its enzymatic activity precludes its efﬁcient
synthesis and secretion and induces apoptosis in eukaryotic cells.
The EGF-3 domain is vital for interaction with heparin and the sub-
sequent activation of latent FSAP.
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